Summary
BeOne Medicines Ltd. (ONC), now identified as BeiGene, Ltd., announced on January 18, 2018, the pricing of a significant public offering of American Depositary Shares (ADSs). The company entered into an Underwriting Agreement with several prominent underwriters, including Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, for the sale of 7,425,750 ADSs at a price of $101.00 per ADS. This offering is expected to generate substantial net proceeds for BeiGene, estimated at approximately $710.2 million, with a potential increase to $757.6 million if underwriters fully exercise their option for additional ADSs. The company plans to allocate these funds towards working capital, general corporate purposes, and crucially, research and development activities. The closing of this offering is anticipated on January 22, 2018, subject to standard closing conditions. This event marks a key capital-raising initiative for the company.
Key Highlights
- 1BeiGene, Ltd. (ONC) priced a public offering of 7,425,750 American Depositary Shares (ADSs) at $101.00 per ADS.
- 2The company entered into an Underwriting Agreement with major financial institutions, including Goldman Sachs and Morgan Stanley.
- 3Estimated net proceeds from the offering are approximately $710.2 million, potentially reaching $757.6 million if the underwriters' option is exercised.
- 4Proceeds are earmarked for working capital, general corporate purposes, and significant investment in research and development.
- 5The offering is expected to close on January 22, 2018, contingent upon customary closing conditions.
- 6The offering was made pursuant to an effective shelf registration statement on Form S-3, indicating prior regulatory clearance for such capital raises.
- 7The company also provided opinions from legal counsel regarding ordinary shares, Cayman Islands tax matters, and PRC tax matters.